Want to see BLSM full AI Analyst Report?
Top Page
BlossomHill Therapeutics, Inc.
(NASDAQ:BLSM)
Select Model
Select Model
Rating:53Neutral
Price Target:―
Action:N/A
Date:09/22/26
The score is held back primarily by weak financial performance (no revenue, widening losses, heavy cash burn, and negative equity). Offsetting this are positive corporate catalysts (encouraging trial update and substantial IPO proceeds) and supportive—but potentially overextended—technical momentum. Valuation remains a constraint due to ongoing losses and no dividend support.
Positive Factors
Clinical pipeline validation
The updated Phase 1/2 results provide meaningful clinical validation for BH-30643 in a difficult, heavily pretreated lung-cancer population. Response, disease control, continued treatment, and tolerability data support further development and could strengthen the pipeline’s strategic value over the next several quarters.
Negative Factors
No revenue and widening losses
The absence of revenue leaves the company dependent on future clinical success, commercialization, or partnerships to establish an operating business. Losses that nearly doubled year over year show that spending demands are rising before any proven revenue stream can support the business.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical pipeline validation
The updated Phase 1/2 results provide meaningful clinical validation for BH-30643 in a difficult, heavily pretreated lung-cancer population. Response, disease control, continued treatment, and tolerability data support further development and could strengthen the pipeline’s strategic value over the next several quarters.
Read all positive factors
BlossomHill Therapeutics, Inc. (BLSM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$802.57M
Dividend YieldN/A
Average Volume (3M)215.29K
Price to Earnings (P/E)―
Beta (1Y)8.51
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees63
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding31,784,908
10 Day Avg. Volume265,141
30 Day Avg. Volume215,293
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-3.53
Price to Sales (P/S)0.00
P/FCF Ratio-9.70
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$36.75Price Target Upside― Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BlossomHill Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA....
BlossomHill Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| EBITDA | -46.65M | -63.58M | -36.05M |
| Net Income | -44.77M | -60.55M | -30.70M |
Balance Sheet | |||
| Total Assets | 124.13M | 162.97M | 106.78M |
| Cash, Cash Equivalents and Short-Term Investments | 95.38M | 136.68M | 100.15M |
| Total Debt | 23.37M | 22.40M | 525.00K |
| Total Liabilities | 42.09M | 294.70M | 179.66M |
| Stockholders Equity | 82.04M | -131.73M | -72.88M |
Cash Flow | |||
| Free Cash Flow | -44.19M | -47.99M | -31.51M |
| Operating Cash Flow | -44.17M | -46.92M | -31.42M |
| Investing Cash Flow | -13.00K | -1.07M | -92.00K |
| Financing Cash Flow | 2.88M | 84.53M | 17.56M |
BlossomHill Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $877.28M | -5.51 | -41.33% | ― | 278712.12% | 26.59% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | $802.57M | -2.36 | 127.76% | ― | ― | ― | |
50 Neutral | $823.61M | -1.58 | 1870.38% | ― | -50.80% | 14.80% | |
50 Neutral | $863.07M | -0.22 | -192.76% | ― | ― | -564.79% | |
50 Neutral | $906.74M | -8.01 | -89.38% | ― | ― | -108.75% | |
45 Neutral | $843.48M | -4.17 | -48.22% | ― | ― | -10.16% |
* General Sector Average
BLSM
BlossomHill Therapeutics, Inc.
22.34
6.34
39.63%
IVA
Inventiva
3.45
-2.07
-37.50%
OLMA
Olema Pharmaceuticals
8.83
0.48
5.75%
FDMT
4D Molecular Therapeutics
15.00
6.56
77.73%
FTH
Faeth Therapeutics
31.55
22.53
249.78%
CADL
Candel Therapeutics
11.29
5.86
107.92%
BlossomHill Therapeutics, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
BlossomHill updates BH-30643 lung cancer trial results
Positive
Sep 15, 2026
On September 15, 2026, BlossomHill Therapeutics reported updated results from its ongoing Phase 1/2 SOLARA trial of BH-30643 in non-small cell lung cancer patients with secondary EGFR resistance mutations such as C797S. The data were showcased in ...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
BlossomHill Therapeutics completes IPO and updates governance
Positive
Aug 10, 2026
On August 10, 2026, BlossomHill Therapeutics, Inc. closed its initial public offering of 9,375,000 shares of common stock at $16.00 per share, generating approximately $150.0 million in gross proceeds before underwriting discounts, commissions and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.